| Autor: |
Robert Brown, James Paul, Nadeem Siddiqui, Els MJJ Berns, G. Bea A. Wisman, Dan Cacsire Castillo-Tong, Caroline Kreuzinger, Ignace Vergote, Adriaan Vanderstichele, Silvia Darb-Esfahani, Jalid Sehouli, Elena Ioana Braicu, Hani Gabra, Paula Cunnea, Alexander Hergovich, Charlotte Wilhelm-Benartzi, Kirsty Flower, Erick Loomis, John Gallon, Nahal Masrour, Chail Koo, Angela Wilson, James M. Flanagan |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22463772.v1 |
| Popis: |
Supplementary Figure S1: Clinical Study Schematic. Supplementary Figure S2: Significant changes in blood DNA methylation at time of ovarian cancer relapse compared to at presentation. Supplementary Figure S3: Methylation profiles of blood DNA at time of ovarian cancer relapse predict overall survival. Supplementary Figure S4: Pyrosequencing Validation of blood DNA at time of ovarian cancer relapse predict overall survival. Supplementary Figure S5. Methylation profile validation of tumour DNA at time of ovarian cancer relapse predicts overall survival. Supplementary Figure S6: Deriving clusters using methylation levels of these 8 probes in blood DNA at the time of presentation neither predicts time to first progression nor overall survival. Supplementary Figure S7. Clonal variation in MLH1- and MLH1+ cell lines. Supplementary Figure S8. Cisplatin treatment and long term growth does not affect cisplatin sensitivity of MLH1+ or MLH1- clones. Supplementary Figure S9. Bisulphite pyrosequencing validates five CpG sites. Supplementary Figure S10. Dinucleotide enrichment analysis. Supplementary Figure S11. Mechanism for platinum-induced methylation changes in MLH1-deficient and -proficient cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
